Drug combo shows potential in treating hepatitis C

10/14/2010 | Reuters

The combination of danoprevir and Roche's experimental drug RG7128 appeared safe and well-tolerated in hepatitis C patients compared with placebo during an early-stage study. Those who received the highest doses of both drugs twice a day demonstrated a significant reduction in viral load after 13 days.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY